Please assess the completion status of the following clinical trial:

Trial Title: Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is age 50 to 79, inclusive~2. Patient has signed informed consent~3. Patient has had lower urinary tract symptoms (LUTS) secondary to BPH for at least 6 months prior to study treatment~4. Patient has a baseline IPSS Score \> 13 at baseline~5. Patient has a prostate size of at least 50 grams and not more than 90 grams, measured by MRI~6. Patient has BPH symptoms refractory to medical treatment or for whom medication is contraindicated, not tolerated or refused~7. Patient must be a candidate for TURP~8. Patient must meet one of the following criteria:~   * Baseline Prostate Specific Antigen (PSA) \<2.5 ng/mL (no prostate biopsy required)~  * Baseline PSA \>2.5 ng/mL and ≤10 ng/mL AND free PSA \> 25% of total PSA (no prostate biopsy required)~  * Baseline PSA \>2.5 ng/mL and ≤10 ng/mL AND free PSA \< 25% of total PSA AND a negative prostate biopsy result (minimum 12 core biopsy)~  * Baseline PSA \>10 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy)~Exclusion Criteria:~1. Active urinary tract infection~2. Biopsy proven prostate or bladder cancer, or any cancer other than basal or squamous cell skin cancer~   * The following patients must undergo prostate biopsy with a minimum of 12 cores and have a negative histopathology report to be enrolled in the study:~     * Patients with digital rectal examination (DRE) findings suspicious for prostate cancer~    * Patients with baseline PSA levels \> 10 ng/mL~    * Patients with baseline PSA levels \>2.5 ng/mL and \< 10ng/mL AND free PSA \< 25% of total PSA~  * Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy and have a negative histopathology report to be enrolled in the study~3. Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (eg multiple sclerosis, Parkinson's disease, spinal cord injuries, etc)~4. Urethral stricture, bladder neck contracture, sphincter abnormalities, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition~5. Patient has taken beta blockers, antihistamines, anticonvulsants, or antispasmodics within 1 week of study treatment AND has not been on the same drug dosage for 6 months with a stable voiding pattern~   • Dosage of these medications should not change during study participation unless medically necessary~6. Patient has taken antidepressants, anticholinergics, androgens or gonadotropin-releasing hormonal analogues within 2 months of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern~7. Patient has taken 5-alpha reductase inhibitors or alpha blockers within 1 month of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern~8. Previous non-medical BPH treatment, including surgery, TURP, needle ablation, microwave or laser therapy, balloon dilation, stent implantation, or any other invasive treatment to the prostate~9. Any known condition that limits catheter-based intervention or is a contraindication to embolization, such as intolerance to a vessel occlusion procedure or severe atherosclerosis.~10. Patient is unable to stop taking anticoagulant, nonsteroidal antiinflammatory drug (NSAID) or anti-platelet therapy for 7 days prior to study treatment~11. Unable to have MRI imaging (eg metal implant including pacemaker, replacement joint, etc)~12. Patient has an asymmetric prostate, with \> 20% difference in size between lobes~13. Cardiac condition including congestive heart failure or arrhythmia, uncontrolled diabetes mellitus, significant respiratory disease or known immunosuppression which required hospitalization within the previous 6 months~14. Baseline serum creatinine level \> 1.8 mg/dl~15. Known upper tract renal disease~16. Cystolithiasis or chronic hematuria within 3 months prior to study treatment~17. Active prostatitis~18. Previous rectal surgery other than hemorrhoidectomy, or history of rectal disease~19. History of pelvic irradiation or radical pelvic surgery~20. Patient is interested in future fertility~21. Coagulation disturbances not normalized by medical treatment~22. Acute urinary retention requiring an indwelling catheter~23. Known major iliac arterial occlusive disease~24. Allergy to iodinated contrast agents~25. Hypersensitivity to gelatin products

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Prostate artery embolization (PAE) (Type: EXPERIMENTAL): Prostate artery embolization using Embosphere Microspheres
- Transurethral resection of the prostate (TURP) (Type: ACTIVE_COMPARATOR): Transurethral Resection of the Prostate (TURP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval